<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973309</url>
  </required_header>
  <id_info>
    <org_study_id>18R5-002</org_study_id>
    <nct_id>NCT01973309</nct_id>
  </id_info>
  <brief_title>A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoMed Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mereo BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and&#xD;
      PK of vantictumab when combined with paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been determined,&#xD;
      up to 10 patients may be enrolled in the cohort-expansion phase to better characterize the&#xD;
      safety, tolerability and PK of vantictumab combined with paclitaxel. Up to approximately 34&#xD;
      patients may be enrolled into the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of vantictumab in combination with paclitaxel in patients with locally recurrent or metastatic breast cancer</measure>
    <time_frame>Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-28 days).</time_frame>
    <description>The maximum tolerated dose (MTD) will be determined in patients treated with vantictumab in combination with paclitaxel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of vantictumab when administered in combination with paclitaxel to patients with locally recurrent or metastatic breast cancer</measure>
    <time_frame>Plasma sample for Pharmacokinetics (PK) analysis to be obtained prior to the vantictumab infusion on Days 0, 14, 56 and 70 and at the end of the vantictumab infusion with paclitaxel infusion on Days 0 and 56.</time_frame>
    <description>Apparent half life, AUC, clearance, volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vantictumab combined with paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: vantictumab combined with paclitaxel - administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vantictumab combined with paclitaxel</intervention_name>
    <description>Vantictumab combined with paclitaxel will be administered IV.</description>
    <arm_group_label>Vantictumab combined with paclitaxel</arm_group_label>
    <other_name>(OMP-18R5)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Histologically documented adenocarcinoma of the breast with locally recurrent or&#xD;
             metastatic disease&#xD;
&#xD;
             o Patients with breast cancer overexpressing HER2 are not eligible.&#xD;
&#xD;
          -  Availability of tumor tissue, either archival FFPE or obtained at study entry through&#xD;
             fresh biopsy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  All acute treatment-related toxicity from prior therapy must have resolved to Grade ≤&#xD;
             1 prior to study entry&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Evaluable or measurable disease per RECIST v1.1&#xD;
&#xD;
          -  For women of childbearing potential, agreement to use two effective forms of&#xD;
             contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known significant dose delays during prior treatment with a taxane due to drug-related&#xD;
             toxicities&#xD;
&#xD;
          -  Prior treatment with more than two regimens of systemic cytotoxic chemotherapy for&#xD;
             locally recurrent or metastatic disease&#xD;
&#xD;
          -  Treatment with any anti-cancer therapy within 3 weeks prior to initiation of study&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center/ Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally Recurrent</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

